Alpelisib

Drug Overview

Alpelisib is a pioneering targeted therapy that specifically inhibits the PI3K-alpha enzyme, a key driver in certain types of breast cancer. It is the first drug of its kind approved for patients with specific genetic mutations, marking a significant step forward in personalized oncology.

• Generic Name: Alpelisib
• US Brand Names: Piqray® (Oncology), Vijoice® (PROS)
• Drug Class: Phosphatidylinositol-3-Kinase (PI3K) Inhibitor (Alpha-Specific)
• Route of Administration: Oral (Tablets)
• FDA Approval Status: Approved for PIK3CA-mutated HR+/HER2- advanced breast cancer and PIK3CA-Related Overgrowth Spectrum (PROS).

What Is It and How Does It Work? (Mechanism of Action)

Alpelisib works by blocking a specific signaling pathway that cancer cells use to grow and survive, particularly when they have become resistant to hormonal therapy.

• Molecular Target: The drug selectively inhibits the p110α isoform of the PI3K enzyme (encoded by the PIK3CA gene).
• Pathway Blockade: The PI3K/AKT/mTOR pathway is crucial for cell metabolism, growth, and survival. In many breast cancers, the PIK3CA gene is mutated, causing this pathway to be permanently “on,” driving tumor growth. Alpelisib binds to the enzyme and turns this signal “off.”
• Overcoming Resistance: By blocking the PI3K pathway, alpelisib restores sensitivity to endocrine (hormone) therapy. When used in combination with fulvestrant (an estrogen receptor degrader), it creates a dual blockade that is more effective than either drug alone.

FDA-Approved Clinical Indications

Alpelisib has distinct approvals for oncology and rare genetic disorders.

Oncological Uses (Piqray®):

• Advanced or Metastatic Breast Cancer: Indicated in combination with fulvestrant for postmenopausal women and men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced or metastatic breast cancer, following progression on or after an endocrine-based regimen.

Non-Oncological Uses (Vijoice®):

• PIK3CA-Related Overgrowth Spectrum (PROS): Indicated for adult and pediatric patients (2 years of age and older) with severe manifestations of PROS who require systemic therapy.

Dosage and Administration Protocols

Alpelisib is an oral medication that must be taken with food to ensure proper absorption.

Standard Oncology Dosage (Breast Cancer):

• Dose: 300 mg (two 150 mg tablets) once daily.
• Frequency: Daily, taken at the same time each day.
• Food Requirement: Must be taken immediately following food. Taking it on an empty stomach significantly reduces its effectiveness.

Dose Modifications for Toxicity:

If side effects occur, the dose is typically reduced in steps:

• First Reduction: 250 mg daily.
• Second Reduction: 200 mg daily.
• Discontinue: If 200 mg is not tolerated.

Clinical Efficacy and Research Results

Clinical trials (2020-2025 context) have established Alpelisib as a standard of care for PIK3CA-mutated breast cancer.

• Progression-Free Survival (SOLAR-1): In the pivotal trial, the combination of Alpelisib + Fulvestrant nearly doubled the median Progression-Free Survival (PFS) compared to Fulvestrant alone (11.0 months vs. 5.7 months) in patients with PIK3CA mutations.
• Overall Survival Benefit: While the primary endpoint was PFS, subgroup analyses showed a clinically meaningful improvement in Overall Survival (OS) for patients with visceral (lung/liver) metastases, extending survival by over 14 months in this high-risk group.
• Real-World Evidence: Studies confirm that testing for the PIK3CA mutation (found in ~40% of HR+ breast cancers) is critical, as patients without the mutation do not benefit from the drug.

Safety Profile and Side Effects

Important Warning:

Alpelisib has a unique side effect profile compared to chemotherapy, specifically metabolic toxicity. Hyperglycemia (High Blood Sugar) is a major concern.

Common Side Effects (>20%)

• Hyperglycemia: Occurs in ~65% of patients. It is a direct result of blocking PI3K, which is involved in insulin signaling.
• Diarrhea: Very common (~58%), ranging from mild to severe.
• Rash: Maculopapular rash affects ~52% of patients, often early in treatment.
• Nausea & Fatigue: Common but generally manageable.

Serious Adverse Events

• Severe Hyperglycemia/Ketoacidosis: Can happen rapidly, even in non-diabetics. Requires immediate insulin or oral anti-diabetic therapy and dose interruption.
• Severe Cutaneous Reactions: Stevens-Johnson Syndrome (SJS) and Erythema Multiforme (EM) have been reported.
• Pneumonitis: Inflammation of the lungs, requiring steroid treatment.

Management Strategies:

• For Hyperglycemia: Prophylactic use of metformin may be recommended for patients with pre-diabetes. Regular fasting glucose monitoring is mandatory.
• For Rash: Prophylactic antihistamines are strongly recommended before starting the drug to prevent rash onset.

Connection to Stem Cell and Regenerative Medicine

Alpelisib’s target, the PI3K pathway, is a master regulator of stem cell maintenance and differentiation.

• Targeting Breast Cancer Stem Cells (BCSCs): Research shows that BCSCs rely heavily on the PI3K pathway for self-renewal and resistance to chemotherapy. Alpelisib has been shown to preferentially inhibit the growth of these stem-like cells in mammosphere assays, potentially reducing the risk of cancer recurrence.
• Regenerative Potential: In regenerative medicine, the drug is used as a tool to understand tissue overgrowth. By inhibiting PI3K in PROS (overgrowth syndrome), alpelisib effectively “corrects” the abnormal growth signals in progenitor cells, reducing the size of vascular malformations and overgrowth lesions.

Patient Management & Practical Recommendations

Pre-Treatment Tests:

• PIK3CA Mutation Test: Mandatory. The drug is only approved for patients with this specific mutation.
• Fasting Plasma Glucose (FPG) & HbA1c: To establish baseline blood sugar status.
• Pregnancy Test: Must be negative.

Precautions During Treatment:

• Glucose Monitoring: Check Fasting Glucose at least once a week for the first 2 weeks, then every 4 weeks.
• Dietary Changes: A low-carbohydrate diet may help manage blood sugar spikes.

Do’s and Don’ts:

• DO: Take the tablet immediately after a meal to ensure proper absorption.
• DO: Take prophylactic non-sedating antihistamines (like cetirizine) if prescribed to prevent rash.
• DON’T: Ignore symptoms like excessive thirst, frequent urination, or blurred vision (signs of high blood sugar).
• DON’T: Crush or chew the tablets.

Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Dosing and protocols may vary by patient status and local regulatory guidelines. Always consult with a qualified oncologist or healthcare provider regarding specific medical conditions.